A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated EGFR-mutant patients with advanced non-small cell lung cancer

BACKGROUND: In recent years, osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been recommended as a first-line treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC). A phase III study (AENEAS) to assess the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Chang, Kejie, Qiu, Xin, Lai, Zhirong, Luo, Yuanling, Chen, Jiaqun, Lv, Weize, Lin, Zhong, Pei, Xiaofeng, Wu, Xiangwen, Wang, Xiaojin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326784/
https://www.ncbi.nlm.nih.gov/pubmed/37425401
http://dx.doi.org/10.21037/tlcr-23-175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326784/
https://www.ncbi.nlm.nih.gov/pubmed/37425401
http://dx.doi.org/10.21037/tlcr-23-175

Ejemplares similares